The FDA has approved Tenpoint Therapeutics' Yuvezzi (carbachol/brimonidine tartrate) eye drops for adults with presbyopia, the first approved dual-action therapy to improve age-related vision.[1] The drops are applied once a day and achieve a narrowing of the pupil (miosis) from 30 minutes to 10 hours.[1] The approval is based on positive data from two pivotal Phase 3 studies with more than 800 patients, including the largest and longest safety study (12 months) with more than 72,000 treatment days.[1] No treatment-related serious adverse events were observed in the BRIO II trial.[1] The most common side effects include headache, visual disturbances, and temporary eye pain or irritation.[1] Eye redness was reported rarely, in BRIO II in 2.8% of patients on Yuvezzi versus 10.7% on carbachol alone.[1]